Shares of Horizon Pharma PLC (NASDAQ:HZNP) ended Thursday session in green amid volatile trading. The shares closed up +0.02 points or 0.11% at $17.85 with 2.08 million shares getting traded. Post opening the session at $17.75, the shares hit an intraday low of $17.64 and an intraday high of $18.11 and the price vacillated in this range throughout the day. The company has a market cap of $2.87 billion and the numbers of outstanding shares have been calculated to be 160.90 million shares.
Horizon Pharma PLC (HZNP) announced that it will present at the Morgan Stanley Global Healthcare Conference at 9:20 a.m. ET on September 12, 2016 in New York City, NY.
The conference presentation, which will include an update of Horizon’s business, will be webcast live and may be accessed by visiting Horizon’s investor relations section of the website at http://ir.horizon-pharma.com. A replay of the webcast will be available for the event.
Shares of Hologic, Inc. (NASDAQ:HOLX) ended Thursday session in red amid volatile trading. The shares closed down -0.17 points or -0.44% at $38.50 with 1.67 million shares getting traded. Post opening the session at $38.58, the shares hit an intraday low of $38.38 and an intraday high of $38.70 and the price vacillated in this range throughout the day. The company has a market cap of $10.73 billion and the numbers of outstanding shares have been calculated to be 277.42 million shares.
Hologic, Inc. (HOLX) on Sept. 8, 2016 announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) for the company’s Aptima® Zika virus diagnostic assay to be used with urine samples (collected alongside patient-matched serum or plasma specimens).
Hologic’s Zika virus assay was authorized for emergency use with serum and plasma (blood) samples in June 2016. Its new use with urine samples lengthens the time period during which patients can be tested for Zika from seven days to 14 days following symptoms, as recommended by the U.S. Centers for Disease Control and Prevention (CDC).
“This action by FDA is significant because it gives many more people the opportunity to be tested with our highly sensitive assay,” said Tom West, Division President of Diagnostic Solutions at Hologic. “In particular, this expanded indication allows us to better serve public health labs, increasing access to more people to detect and diagnose more disease.”
The Aptima Zika Virus assay runs on Hologic’s Panther® system, a market-leading, integrated platform that fully automates all aspects of nucleic acid amplification testing. By reducing hands-on time, the Panther system helps to minimize labor needs and the potential for manual errors. The Aptima Zika Virus assay is available for use in all 50 states, Puerto Rico and U.S. territories.
“We are driven to provide solutions to some of society’s most urgent unmet health needs,” said Steve MacMillan, Chairman, President and Chief Executive Officer of Hologic. “The suspension of the Medical Device Excise Tax enabled us to make additional investments in research and development and accelerate availability of this critically important test.”